MSH2 and prostate carcinoma: Whole genome sequencing of two prostate cancer samples, one with a functional MMR system (G089, a late stage prostate cancer patient) and other with deficiency of the MMR system (PC346C, a prostate cancer cell line with point mutations in both alleles of the MSH2 gene) [30] identified numerous novel gene mutations.